Diabetes and CV Disease: An Uneasy Truce

Abrams, Jonathan
October 2009
Internal Medicine Alert;10/15/2009, Vol. 31 Issue 19, p148
The authors of this meta-analysis conclude that their results support the use of aggressive insulin-lowering therapy to reduce major CV outcomes but not all-cause mortality; further, they recommend vigilance in avoiding hypoglycemia while steadily reducing HbA1c.


Related Articles

  • Computational evaluation of the dynamic minimal model for the root causes of hypoglycemia. Tunç, Murat; Şişbot, Sedat; Kaya Gülkaya, A. // Journal of Biomedical Science & Engineering;May2011, Vol. 4 Issue 5, p391 

    This research is an attempt to validate how glucose-insulin dynamic mathematical model facilitate to identify the root causes for hypoglycaemia. The purpose is to determine whether increased insulin sensitivity or increased insulin secretion causes postprandial hypoglycemic (PPH) response, by...

  • Hypoglycemia and Cardiovascular Risks. FRIER, BRIAN M.; SCHERNTHANER, GUNTRAM; HELLER, SIMON R. // Diabetes Care;May2011 Supplement 2, Vol. 34, pS132 

    The article examines the effects of hypoglycemia on the cardiovascular (CV) system. According to the findings of a study by the U. K. Hypoglycemia Study Group, it was revealed that severe hypoglycemia is a common problem in insulin-treated type 2 diabetes. Example of hemodynamic changes...

  • Management - Complications and Comorbidities.  // Current Medical Literature: Diabetes;2008, Vol. 25 Issue 2, p63 

    The article presents abstracts on diabetes which include the influence of elevated cardiometabolic risk factor levels on treatment changes in type 2 diabetes, the effects of controlled hypoglycaeima on cardiac repolarisation in patients with type 1 diabetes and the benefits of rosiglitazone on...

  • Case Study: Exercise-Related Hypoglycemia in Type 2 Diabetes Treated With Oral Glucose-Lowering Medications. Hayes, Charlotte // Clinical Diabetes;Fall2007, Vol. 25 Issue 4, p150 

    The article focuses on exercise-related hypoglycemia in type 2 diabetes treated with oral glucose-lowering medications. It says that the medications of a diabetic 58-year-old man was modified by discontinuing glyburide and initiating glimepiride. It states that multiple metabolic adaptations to...

  • Management of Type 2 Diabetes.  // Current Medical Literature: Diabetes;2012, Vol. 29 Issue 2, p44 

    The article discusses studies on type 2 diabetes management. One study examined whether loss of fat, fluid or lean tissue caused the associated weight loss from the administration of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2). Another study focused on a post hoc...

  • Severe hypoglycemia increased risk for major macrovascular, microvascular events. Ellis, Brian // Cardiology Today;Nov2010, Vol. 13 Issue 11, p1 

    This article focuses on a study published in "The New England Journal of Medicine" which examined the relationship between severe hypoglycemia and the risks for macrovascular and microvascular events in patients with type 2 diabetes.

  • Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Kanters, S.D.; Banga, J-D.; Stolk, R.P.; Algra, A. // Vascular Medicine;1999, Vol. 4 Issue 2, p67 

    Patients with diabetes mellitus are at increased risk of developing atherosclerotic disease. The extent of this additional risk and its determinants are not well known, but this information is needed for sample-size estimations in intervention studies. Therefore, a meta-analysis of epidemiologic...

  • A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events. Gangji, Azim S.; Cukierman, Tali; Gerstein, Hertzel C.; Goldsmith, Charles H.; Clase, Catherine M. // Diabetes Care;Feb2007, Vol. 30 Issue 2, p389 

    OBJECTIVE -- Glyburide is the most widely used sulfonylurea but has unique pharmacodynamic properties that may increase harm. We hypothesized that glyburide causes more hypoglycemia and cardiovascular events than other secretagogues or insulin. RESEARCH DESIGN AND METHODS -- Data sources were...

  • Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors. Stonhouse, Anthony; Okerson, Ted; Kendall, David; Maggs, David // Current Diabetes Reviews;2008, Vol. 4 Issue 2, p101 

    Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics